Mattson Financial Services LLC Has $2.57 Million Holdings in Pfizer Inc. $PFE

Key Points

• Mattson Financial Services LLC increased its holdings in Pfizer Inc. by 23.3%, owning 101,393 shares worth approximately $2.57 million by the end of the first quarter.
• Pfizer reported an earnings per share of $0.78 for the quarter, exceeding analysts' expectations of $0.58, with revenues reaching $14.65 billion, up 10.3% year-over-year.
• The company recently announced a quarterly dividend of $0.43 per share, translating to a 7.0% yield for investors.

Mattson Financial Services LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 23.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 101,393 shares of the biopharmaceutical company's stock after purchasing an additional 19,189 shares during the quarter. Mattson Financial Services LLC's holdings in Pfizer were worth $2,569,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in PFE. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the 1st quarter worth approximately $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the 1st quarter worth approximately $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the 1st quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 3.8%

Shares of Pfizer stock traded down $0.95 on Friday, hitting $23.91. 81,158,118 shares of the company's stock traded hands, compared to its average volume of 34,996,196. The firm's 50-day moving average price is $24.79 and its two-hundred day moving average price is $24.30. The stock has a market capitalization of $135.94 billion, a PE ratio of 12.72, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the company earned $0.60 EPS. The firm's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer's dividend payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

PFE has been the topic of several recent analyst reports. Jefferies Financial Group boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank dropped their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.